[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [JCR Pharmaceuticals Co. Ltd.](/topic/$4552t) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "AstraZeneca and AAV research AstraZeneca through its rare disease unit Alexion is actively involved in developing AAV-based gene therapies. Collaboration deals: In July 2025 Alexion partnered with JCR Pharmaceuticals in an $XXX million deal to acquire AAV capsids for up to five genomic medicine programs. The company has also previously acquired AAV assets from Pfizer. Internal development:AstraZeneca also conducts its own AAV research including developing improved vectors and novel capsids to increase delivery accuracy and improve safety. Keir Starmer and the UK life sciences sector Prime" [X Link](https://x.com/NotTheMacAnon1/status/1980196322935198204) [@NotTheMacAnon1](/creator/x/NotTheMacAnon1) 2025-10-20T08:56Z 3813 followers, XX engagements "JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology" [X Link](https://x.com/NewsFromBW/status/1975640590571479161) [@NewsFromBW](/creator/x/NewsFromBW) 2025-10-07T19:13Z 4028 followers, XX engagements "The blood-brain barrier (BBB) is a selective frontier that protects the brain from harmful substances but also blocks the passage of many potential treatments. For researchers and companies in pharma and biotech finding strategies to cross this barrier safely and effectively is crucial. JCR Pharmaceuticals has developed an innovative therapy capable of binding to transferrin receptors enabling targeted delivery of biomedicines across the BBB. This approach opens new possibilities for addressing neurological and rare disorders that until now were extremely difficult to treat. We had the" [TikTok Link](https://www.tiktok.com/@3dforscience.com/video/7550277561738202390) [@3dforscience.com](/creator/tiktok/3dforscience.com) 2025-09-15T11:33Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"AstraZeneca and AAV research AstraZeneca through its rare disease unit Alexion is actively involved in developing AAV-based gene therapies. Collaboration deals: In July 2025 Alexion partnered with JCR Pharmaceuticals in an $XXX million deal to acquire AAV capsids for up to five genomic medicine programs. The company has also previously acquired AAV assets from Pfizer. Internal development:AstraZeneca also conducts its own AAV research including developing improved vectors and novel capsids to increase delivery accuracy and improve safety. Keir Starmer and the UK life sciences sector Prime"
X Link @NotTheMacAnon1 2025-10-20T08:56Z 3813 followers, XX engagements
"JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology"
X Link @NewsFromBW 2025-10-07T19:13Z 4028 followers, XX engagements
"The blood-brain barrier (BBB) is a selective frontier that protects the brain from harmful substances but also blocks the passage of many potential treatments. For researchers and companies in pharma and biotech finding strategies to cross this barrier safely and effectively is crucial. JCR Pharmaceuticals has developed an innovative therapy capable of binding to transferrin receptors enabling targeted delivery of biomedicines across the BBB. This approach opens new possibilities for addressing neurological and rare disorders that until now were extremely difficult to treat. We had the"
TikTok Link @3dforscience.com 2025-09-15T11:33Z XXX followers, XXX engagements
/topic/$4552t/posts